Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jayne Swain"'
Autor:
Fiona Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul Nathan, Robert Jones, David Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky Goh, David Buckley, Jenny Hewison, Walter Gregory, Peter Selby, Julia Brown, Janet Brown
Publikováno v:
Health Technology Assessment, Vol 28, Iss 45 (2024)
Background There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. Trial design A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment
Externí odkaz:
https://doaj.org/article/f262d31cdee84d25b7afd7439e0362e7
Autor:
Jon Griffin, Jenny Down, Lewis A Quayle, Paul R Heath, Ewan A Gibb, Elai Davicioni, Yang Liu, Xin Zhao, Jayne Swain, Dennis Wang, Syed Hussain, Simon Crabb, James WF Catto, the GUSTO Trial Management Group
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 2, Pp n/a-n/a (2024)
Abstract The GUSTO clinical trial (Gene expression subtypes of Urothelial carcinoma: Stratified Treatment and Oncological outcomes) uses molecular subtypes to guide neoadjuvant therapies in participants with muscle‐invasive bladder cancer (MIBC). B
Externí odkaz:
https://doaj.org/article/4fef0e3838804e81a865003240a3ce8e
Autor:
Mairéad G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 102015- (2023)
Summary: Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no stan
Externí odkaz:
https://doaj.org/article/17e61c62deeb4eef9d3d7c4b9df3c376
Autor:
Jim Zhong, Ebrahim Palkhi, David L. Buckley, Fiona J. Collinson, Christy Ralph, Satinder Jagdev, Naveen S. Vasudev, Jayne Swain, Janet E. Brown, Tze Min Wah
Publikováno v:
Diagnostics, Vol 11, Iss 7, p 1302 (2021)
Objective: To identify dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters predictive of early disease progression in patients with metastatic renal cell cancer (mRCC) treated with anti-angiogenic tyrosine kinase inhibitors (TKI
Externí odkaz:
https://doaj.org/article/4d6d2aafbb954842b324eda9760a2653
Autor:
Jennifer S Walsh, Helen Marshall, Isabelle L Smith, Diana M Greenfield, Jayne Swain, Emma Best, James Ashton, Julia M Brown, Robert Huddart, Robert E Coleman, John A Snowden, Richard J Ross
Publikováno v:
PLoS Medicine, Vol 16, Iss 11, p e1002960 (2019)
BackgroundYoung male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low testosterone in cancer survivors can be due to orchidectomy or effects of chemotherapy and r
Externí odkaz:
https://doaj.org/article/f49fdd1e7541450b898e454275658b2b
Autor:
Janet E Brown, Kara-Louise Royle, Walter Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, Rhona McMenemin, Poulam Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter Selby, Fiona Collinson, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, Marios Decatris, Carys Thomas, Joanna Gale, James McAleer, Alison Clayton, Ekaterini Boleti, Thomas Geldart, Santhanam Sundar, Jason Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, Rajaguru Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, Nicholas Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, Sharon Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela Scott, Mark Baxter, Anna Mullard, Pasquale Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry Taylor, Christos Mikropoulos, Martin Highley, Dakshinamoorthy Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, Urmila Barthakur, Erica Beaumont, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti
Publikováno v:
STAR Investigators, Brown, J E, Royle, K-L, Gregory, W, Ralph, C, Maraveyas, A, Din, O, Eisen, T, Nathan, P, Powles, T, Griffiths, R, Jones, R, Vasudev, N, Wheater, M, Hamid, A, Waddell, T, McMenemin, R, Patel, P, Larkin, J, Faust, G, Martin, A, Swain, J, Bestall, J, McCabe, C, Meads, D, Goh, V, Min Wah, T, Brown, J, Hewison, J, Selby, P & Collinson, F 2023, ' Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial ', Lancet Oncology, vol. 24, no. 3, pp. 213-227 . https://doi.org/10.1016/S1470-2045(22)00793-8
Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional conti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a633cdaf72543d0ca87f46d23005d79
https://doi.org/10.1016/s1470-2045(22)00793-8
https://doi.org/10.1016/s1470-2045(22)00793-8
Autor:
Jonathan Wadsley, Gemma Ainsworth, Amy Beth Coulson, Kate Garcez, Laura Moss, Kate Newbold, Kate Farnell, Jayne Swain, Helen Howard, Matthew Beasly, Andrew Weaver, Katie Wood, Jennifer Marshall, Matthew Griffin, Abigail Pascoe, Yong Du, Jan Taprogge, Glenn Flux, Sarah Brown
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0dd8cffc041fb3c29679295d3790987
https://doi.org/10.2139/ssrn.4143123
https://doi.org/10.2139/ssrn.4143123
Autor:
Zoe Craig, Jayne Swain, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nicholas Simon Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard A Hubner, Juan W. Valle, Mairead Geraldine McNamara
Publikováno v:
Journal of Clinical Oncology. 40:293-293
293 Background: NET-02 was a multi-centre, randomised (1:1), non-comparative phase II trial of nal-IRI/5-FU/folinic acid (ARM A) or docetaxel (ARM B) in pts with progressive PD-EP-NEC, aimed at selecting a treatment for evaluation in a phase III tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1157a84011b8236915d2389c7d6ba82
https://doi.org/10.1200/jco.2022.40.28_suppl.293
https://doi.org/10.1200/jco.2022.40.28_suppl.293
Autor:
Olusola Olusesan Faluyi, Emma Batman, Ian Chau, Debashis Sarker, David A Cairns, Mairéad G McNamara, Judith Cave, Nicholas S. Reed, Juan W. Valle, Helen Howard, Angela Lamarca, Jonathan Wadsley, R Hubner, Jayne Swain, Zoe Craig, Wasat Mansoor, Tim Meyer, Lucy Wall, Rohini Sharma
Publikováno v:
Craig, Z, Swain, J, Batman, E, Wadsley, J, Reed, N, Faluyi, O, Cave, J, Rohini, S, Chau, I, Wall, L, Lamarca, A, Hubner, R, Mansoor, W, Sarker, D, Meyer, T, Cairns, D A, Howard, H, Valle, J & Mcnamara, M 2020, ' NET-02 trial protocol : A multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC) ', BMJ Open, vol. 10, no. 2, e034527, pp. e034527 . https://doi.org/10.1136/bmjopen-2019-034527
e034527
BMJ Open
e034527
BMJ Open
IntroductionPoorly differentiated (PD), extrapulmonary (EP), neuroendocrine carcinomas (NECs) are rare but aggressive neuroendocrine neoplasms. First-line treatment for advanced disease is an etoposide and platinum-based chemotherapy combination. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97ec48177b86e441f2cdf28923503289
https://eprints.soton.ac.uk/478146/
https://eprints.soton.ac.uk/478146/
Autor:
Richard A Hubner, Jayne Swain, Helen Howard, Nicholas S. Reed, Zoe Craig, David A Cairns, Tim Meyer, Wasat Mansoor, Juan W. Valle, Mairéad G McNamara, Debashis Sarker, Jonathan Wadsley, Angela Lamarca, Olusola Olusesan Faluyi
Publikováno v:
Journal of Clinical Oncology. 37:TPS4158-TPS4158
TPS4158 Background: The prognosis for pts with PD-EP-NEC is poor. First-line treatment for advanced disease is etoposide/platinum-based chemotherapy, analogous to that of high grade lung NEC, with no standard second-line treatment, and is an area of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ca577de4d0e43f2747cde6e7649d226
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4158
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4158